View Older Stories
-
Teva Pharma (TEVA) PT Raised to $19 at RBC Capital
-
Pre-Open Movers 05/16: (BOOT) (ABAX) (M) Higher; (VSTM) (SRAX) (ABR) Lower (more...)
-
Teva Pharma (TEVA) PT Lowered to $16 at RBC Capital After Cutting Out-Year Estimates
-
RBC Capital Upgrades Teva Pharma (TEVA) to Sector Perform
-
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
-
Teva Pharma (TEVA): A Price Below $8 Is Real - RBC
-
Teva Pharma (TEVA): Cutting PT To $13 On Ongoing Copaxone Pressures - RBC
-
Teva Pharma (TEVA): Good Announcements But Back-Drop Unchanged, Cutting PT - RBC
-
RBC Capital Double Downgrades Teva Pharma (TEVA) to Underperform
-
Teva Pharma (TEVA): Cutting EPS Ahead Of Quarterly Results - RBC
-
Teva Pharma (TEVA): Cutting PT After Sector Revisit - RBC
-
EpiPen maker Mylan forecasts strong 2017; shares jump
-
Teva Pharma (TEVA): Copaxone Delay A Positive - RBC
-
RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
-
Teva CEO exits in ongoing crisis of confidence at drugmaker
-
Teva Pharma (TEVA): Street is Too High, Cutting PT - RBC
-
Teva Pharma (TEVA): Cutting PT "Well Below" Consensus - RBC
-
Notable Analyst Rating Changes 11/4: (ACHN) (MMC) (HCP) Upgraded; (AXL) (BRO) (WFM) Downgraded
-
Notable 52-Week Highs and Lows 10/17: (CTRV) (IGT) (TCK) High; (TEVA) (OPB) (ANF) Low
-
Allergan pays top dollar for 'stepping stones' from neurology to dermatology
-
Teva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics
-
Teva Pharma (TEVA): Setting Up For a Rebound - RBC
-
Teva Pharma (TEVA): Estimates Fall On Actavis - RBC
-
Notable Mergers and Acquisitions 6/21: (IPXL) (OSIS)/(ASEI) (TCEHY) (PHG)
-
Notable Mergers and Acquisitions 6/21: (IPXL) (OSIS)/(ASEI) (TCEHY) (PHG)
-
Impax Laboratories (IPXL) to Acquire Generics Portfolio from Teva, Allergan; Updates FY16 Outlook
-
TREANDA Ruling Positive for Eagle Pharma (EGRX) and Teva (TEVA); Removes Huge Uncertainty for EGRX - RBC
-
Notable Analyst Rating Changes 5/4: (DG) (FDX) (PLT) Upgraded; (KBH) (MOH) (RLYP) Downgraded
-
Teva Pharma (TEVA) Underwriters Exercise Overallotment Option in Latest Offering
-
Teva Announces Exercise of Underwriters’ Over-Allotment Option
-
Teva Announces Closing of Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Actavis Generics
-
Notable Analyst Rating Changes 12/4: (TEVA) (HBI) (HPP) Upgraded; (M)( GPRO) (KSU) Downgraded
-
Teva Announces Pricing of Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Actavis Generics
-
Teva Pharma (TEVA) Announces ~$6.75B ADS, Conv. Preferred Offering
-
Teva Announces Proposed Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Actavis Generics
-
Teva Pharma (TEVA) Secures $33.75B Financing Commitment Relating to Pending Acquisition of Allergan's Generic Business
-
Teva Secures $33.75 Billion Financing Commitment
-
Vivus (VVUS) Defends Qsymia IP from Another Generic Giant, RBC Capital Comments
-
Notable 52-Week Highs and Lows 3/23: (PFE) (TEVA) (DRI) High; (MEIP) (SONS) (YOKU) Low
-
Notable Mergers and Acquisitions 3/18: (TEVA)/(RXDX) (MSCC)/(VTSS) (MGLN)
-
RBC Comments on Amgen (AMGN) Repatha Data
-
Notable Analyst Rating Changes 1/26: (BBBY) (GRMN) (FNFG) Upgraded; (HCP) (STT) (LYB) Downgraded
-
RBC Capital Upgrades Teva Pharma (TEVA) to Outperform
-
Notable Analyst Rating Changes 04/16: (SFUN) (TWTR) (YELP) Upgraded; (INTC) (UNH) (GDP) Downgraded
-
RBC Capital Starts Teva Pharma (TEVA) at Sector Perform
-
Notable Analyst Rating Changes 10/24: (BHP) (XL) (USU) Upgraded; (WEN) (IFF) (TEVA) Downgraded
-
Notable Analyst Rating Changes 08/18: (SINA) (UDR) (BIIB) Upgraded; (NTAP) (GT) (IR) Downgraded
-
Notable 52-Week Highs and Lows of the Day 08/01: (MPEL) (JAZZ) (CROX) High; (SUNH) (TEVA) (HCA) Low
-
Notable Analyst Rating Changes 04/19: (ZION) (NAV) (RBN) Upgraded; (GS) (ABAT) (CRU) Downgraded
-
David Moenning's Daily State of the Markets: 3/13